Agenda: Day Three (April 11th) > Arrowhead Publishers

8:00-9:00 Breakfast

9:00-9:10 Chair’s opening remarks
Dr. Igor Gonda, President & CEO, Aradigm Corp.

9:10 New Transdermal Drug Delivery Technology: The PassPort System
Altea Therapeutics new transdermal technology, the PassPort System, enables the sustained transdermal delivery of water-soluble drugs, peptides, proteins, and nucleotides from a convenient and cost-effective skin patch. The company has extensive experience using the PassPort System, and is in clinical development for:

Fentanyl citrate transdermal patch for safe and rapid management of chronic moderate to severe pain
12-hour and 24-hour transdermal patch providing basal levels of insulin for treating type 1 and type 2 diabetes
Apomorphine hydrochloride patch which provides continuous delivery of apomorphine for managing Parkinson’s symptoms and reducing daily ‘off’ time

Mr. Steven Damon, Vice President Business Development, Altea Therapeutics

9:50 Pulmonary Drug Delivery: Where Do We Go From Here? Further expansion of this market is expected due to the therapeutic advantages of selective targeting of drugs to the airways and lungs for the treatment of respiratory disease, as well as through the emerging field of systemic delivery via the lung that is likely to undergo growth acceleration as a result of approval of inhaled insulin.

This session will provide an overview of the current state of pulmonary drug delivery and provide insight into the future of this market.

Key topics include:

The expansion of the respiratory market
Key technologies: pMDI, passive & active DPIs, nebulizers, soft mists
Formulations: “Immediate release”
Growth of the pulmonary route for systemic delivery

Dr. Igor Gonda, President & CEO, Aradigm Corp.

10:30 Synthetic Gene Delivery and Plasmid DNA-based Pharmaceuticals
This session will describe the design of synthetic gene delivery systems and their applications to the development of plasmid DNA (pDNA)-based biopharmaceuticals. It will exemplify the optimization of cationic lipid- and block copolymer-based systems to modulate the cellular and/or humoral immune responses and their applications to the development of prophylactic and therapeutic infectious disease vaccines. The presentation will include:

A roadmap to the development of pDNA-based product candidates
The design and application of a polymer-based system to the development of an immunotherapeutic infectious disease vaccine
The design and applications of cationic lipid-based delivery systems to the development of prophylactic infectious disease vaccines

Dr. Alain Rolland, Sr. VP Product Development, Vical Inc.

11:10 Close of Conference

Arrowhead Conferences